London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.
What happened
FDA inspected the company's London drug manufacturing facility from September 15 to 19, 2025. Investigators found batches of homeopathic drugs, including products labeled for children as young as two, released without testing for objectionable microorganisms, and expiration dates extended without stability data to support them. FDA also found that quality records, including analytical forms with failing results, were discarded, and one batch was detained and refused admission at the U.S. border after FDA testing found microbiological contamination.
What FDA found
The company released batches of drug product without testing each batch to confirm it was free of objectionable microorganisms.
21 CFR 211.165(b)The company extended expiration dates beyond what its stability data supported, so shelf-life claims were not backed by evidence.
The quality unit lacked adequate written procedures and oversight, and CGMP records such as manufacturing records and finished product specification forms were not properly kept.
21 CFR 211.22(d)An out-of-trend result noted on a handwritten sticky note was found among discarded materials and was never documented or investigated.
21 CFR 211.22(d)Duplicate records were printed without a procedure to track issuance and reconciliation, and analytical forms with unacceptable results were thrown away instead of triggering investigations.
21 CFR 211.22(d)
What FDA wants
FDA tells the company to respond in writing within 15 working days describing what it has done and will do to fix these violations and prevent recurrence. The letter also asks for full chemical and microbial testing of retain samples, a quality unit assessment and remediation plan, a data integrity investigation and risk assessment, and a qualified CGMP consultant to perform a six-system audit.
Who should pay attention
- brands and distributors selling homeopathic or children's remedies made by this contract manufacturer
- U.S. importers and retailers of UK-made homeopathic drugs
- companies that rely on a supplier's batch release and stability data
This is a summary. Read the original letter on fda.gov.